PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34428264-6 2021 The E. coli ESBL isolates not only showed resistance to third generation cephalosporins but also to antibiotics from other groups, such as fluoroquinolones, aminoglycosides and sulfonamides. Aminoglycosides 157-172 EsbL Escherichia coli 12-16 29912337-12 2018 The isolate also carried blaCTX-M-55, which encodes an ESBL conferring resistance to aztreonam (which completed its resistance to all clinically available beta-lactams), and rmtB, which mediates high-level resistance to aminoglycosides, on an IncFII plasmid. Aminoglycosides 220-235 EsbL Escherichia coli 55-59 32766294-2 2020 The production of ESBL is primarily plasmid mediated, and such plasmids often comprise the genes that encode resistance to other classes of antimicrobials, such as aminoglycosides and fluoroquinolones. Aminoglycosides 164-179 EsbL Escherichia coli 18-22 32120467-8 2019 ABST of ESBL producers revealed high resistance rates for quinolones (41%) and >80% sensitivity for nitrofurantoin, fosfomycin, mecillinam, aminoglycosides and carbapenems. Aminoglycosides 148-163 EsbL Escherichia coli 8-12 32120467-12 2019 >80% ESBL organisms show high sensitivity for aminoglycosides, carbapenems, nitrofurantoin, mecillinam and fosfomycin. Aminoglycosides 54-69 EsbL Escherichia coli 5-9 31629516-7 2019 Both farms used narrow-spectrum penicillin combined with aminoglycosides for drying off, and the majority of ESBL isolates (93%) were co-resistant to aminoglycosides. Aminoglycosides 150-165 EsbL Escherichia coli 109-113 29748922-1 2019 Fluoroquinolones and aminoglycosides offer effective therapy for extended-spectrum beta-lactamase (ESBL)-producing enterobacterial infections, but their usefulness is threatened by increasing resistant strains. Aminoglycosides 21-36 EsbL Escherichia coli 99-103 28061852-0 2017 The occurrence of ESBL-producing Escherichia coli carrying aminoglycoside resistance genes in urinary tract infections in Saudi Arabia. Aminoglycosides 59-73 EsbL Escherichia coli 18-22 29290230-8 2017 This aminoglycoside remains active against the majority of ESBL strains and can be prescribed in once-daily dose allowing also ambulatory management of patients from pediatric emergency department. Aminoglycosides 5-19 EsbL Escherichia coli 59-63 28457027-12 2017 A number of old antibiotic compounds such as Polymyxins, Fosfomycin, and Aminoglycosides are re-emerging as valuable alternatives for the treatment of ESBL producing bacteria. Aminoglycosides 73-88 EsbL Escherichia coli 151-155 26904015-0 2016 Multiple ESBL-Producing Escherichia coli Sequence Types Carrying Quinolone and Aminoglycoside Resistance Genes Circulating in Companion and Domestic Farm Animals in Mwanza, Tanzania, Harbor Commonly Occurring Plasmids. Aminoglycosides 79-93 EsbL Escherichia coli 9-13 27092771-7 2016 More than 95% of non extended-spectrum beta-lactamase (ESBL)-producing E. coli were susceptible to nitrofurantoin, fosfomycin, cefotaxime and aminoglycosides. Aminoglycosides 142-157 EsbL Escherichia coli 55-59 25398058-9 2015 Although 52.4% and 66.7% of the ESBL-producing isolates were susceptible to piperacillin/tazobactam and cefepime, respectively, 96.7% of all the isolates and 90.5% of the ESBL-producing isolates were susceptible to piperacillin/tazobactam or cefepime in combination with aminoglycoside. Aminoglycosides 271-285 EsbL Escherichia coli 32-36 26464143-0 2015 Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli or Klebsiella pneumoniae. Aminoglycosides 0-14 EsbL Escherichia coli 68-100 26167826-16 2015 According to the results of our study, the most effective drugs for ESBL-producing isolates were piperacillin-tazobactam among inhibitor combinations, amikacin among aminoglycosides and nitrofurantoin among orally-used drugs. Aminoglycosides 166-181 EsbL Escherichia coli 68-72 25398058-10 2015 In conclusion, the ESBL group did not show a significantly unfavorable outcome, and empirical therapy with piperacillin/tazobactam or cefepime in combination with aminoglycoside might be more useful for febrile neutropenic children, instead of beta-lactam monotherapy in institutions with high prevalence of ESBL-producing E. coli and K. pneumoniae. Aminoglycosides 163-177 EsbL Escherichia coli 308-312 24856867-6 2014 Furthermore, ESBL-producing E. coli from stool samples were significantly more resistant to fluoroquinolones, aminoglycosides and/or trimethoprim-sulfamethoxazole than chicken isolates. Aminoglycosides 110-125 EsbL Escherichia coli 13-17 23834784-10 2014 Moreover, previous exposure to third-generation cephalosporins (p < 0.001) and aminoglycosides (p < 0.001) was associated with the selection of ESBL-producing E. coli. Aminoglycosides 82-97 EsbL Escherichia coli 150-154 22882781-7 2012 The proportion of ESBL-producing bacteria that were resistant to antibiotics was 83.1% for trimethoprim/sulfamethoxazole, 18.2% for nitrofurantoin, 47.3% for quinolones, and 39.9% for aminoglycosides. Aminoglycosides 184-199 EsbL Escherichia coli 18-22 23519865-12 2013 PA ESBL-E. coli are not more prevalent in community acquired than nosocomial urine samples, but are more often susceptible to ciprofloxacin and aminoglycosides than non-PA ESBL-E. coli. Aminoglycosides 144-159 EsbL Escherichia coli 3-7 23336201-7 2012 Most (85%) of the isolates were positive to ESBL and majority of them produced CTX-M. Target substitution and production of methylases were the main mechanisms causing resistance to fluoroquinolones and aminoglycosides respectively. Aminoglycosides 203-218 EsbL Escherichia coli 44-48 21183602-6 2011 ESBL-producing strains exhibited frequent co-resistance to aminoglycosides and ciprofloxacin, but remained susceptible to imipenem. Aminoglycosides 59-74 EsbL Escherichia coli 0-4 23178131-6 2012 Aminoglycosides have a very good distribution in the renal parenchyma and are still working on the majority of ESBL-producing bacteria. Aminoglycosides 0-15 EsbL Escherichia coli 111-115 21503400-9 2011 Among ESBL-producing K. pneumoniae, 74.3% transferred ESBL genes by conjugation and exhibited concomitant decreased aminoglycosides susceptibility. Aminoglycosides 116-131 EsbL Escherichia coli 6-10 21503400-9 2011 Among ESBL-producing K. pneumoniae, 74.3% transferred ESBL genes by conjugation and exhibited concomitant decreased aminoglycosides susceptibility. Aminoglycosides 116-131 EsbL Escherichia coli 54-58 20464329-4 2009 An ESBL-EK isolate was defined as MDR if it was resistant to at least one member of following two classes of antibiotics: aminoglycosides (amikacin, gentamicin, or netilmycin) and fluoroquinolones (ofloxacin, or ciprofloxacin). Aminoglycosides 122-137 EsbL Escherichia coli 3-7 20387724-6 2010 ESBL-producing K. pneumoniae showed high resistance rates to aminoglycosides, cotrimoxazole, nitrofurantoin and quinolones while ESBL-producing E. coli isolates, with exception of high aminoglycoside resistance, showed low resistance rates to other antibiotics. Aminoglycosides 61-76 EsbL Escherichia coli 0-4 20387724-6 2010 ESBL-producing K. pneumoniae showed high resistance rates to aminoglycosides, cotrimoxazole, nitrofurantoin and quinolones while ESBL-producing E. coli isolates, with exception of high aminoglycoside resistance, showed low resistance rates to other antibiotics. Aminoglycosides 61-75 EsbL Escherichia coli 0-4 21475532-5 2009 Many ESBL producers are multi -resistant to non-B-Lactam antibiotics such as quinolones and amino glycosides, narrowing treatment options. Aminoglycosides 92-108 EsbL Escherichia coli 5-9 18051801-7 2007 ESBL-producing E. coli were sensitive to the following antibiotics: carbapenem; cephamycin; aminoglycoside; and synthesized penicillin. Aminoglycosides 92-106 EsbL Escherichia coli 0-4 12558458-9 2003 Many ESBL-producing organisms also express AmpC beta-lactamases and may be co-transferred with plasmids mediating aminoglycoside resistance. Aminoglycosides 114-128 EsbL Escherichia coli 5-9 17581932-9 2007 ESBL-producing E. cloacae showed resistance to quinolones and aminoglycosides. Aminoglycosides 62-77 EsbL Escherichia coli 0-4 11320450-5 2001 ESBL strains showed high levels of co-resistance to aminoglycosides, tetracycline, trimethoprim-sulfamethoxazole, and ciprofloxacin. Aminoglycosides 52-67 EsbL Escherichia coli 0-4